ethyl 5-(4-bromophenyl)-1-ethyl-1H-pyrazole-3-carboxylate | 1020236-41-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 5-(4-bromophenyl)-1-ethyl-1H-pyrazole-3-carboxylate
• 英文别名: ethyl 5-(4-bromophenyl)-1-ethylpyrazole-3-carboxylate
• CAS: 1020236-41-2
• 化学式: C₁₄H₁₅BrN₂O₂
• 分子量: 323.189
• InChiKey: CFGNBNPGULLJHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Phenyl substituted pyrazoles as modulators of RORγt
  申请人：Janssen Pharmaceutica NV

  公开号：US10975037B2

  公开（公告）日：2021-04-13

  The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

  本发明包括式 I 的化合物。 其中 R1、R3、R4、R5、R6、R7、R8 和 Q 的定义见说明书。 本发明还包括一种治疗或改善 ROR-γ-t 介导的综合征、紊乱或疾病的方法，其中综合征、紊乱或疾病选自由类风湿性关节炎、银屑病关节炎和银屑病组成的组。本发明还包括一种通过施用治疗有效量的至少一种式 I 化合物来调节哺乳动物体内 RORγt 活性的方法。
• [EN] PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORYT<br/>[FR] PYRAZOLES SUBSTITUÉS PAR PHÉNYLE UTILISÉS EN TANT QUE MODULATEURS DE RORYT
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019243999A1

  公开（公告）日：2019-12-26

  The present invention comprises compounds of Formula (I). wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-y-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORĻγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).